- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04259411
MitraClip China PMS
A Prospective, Multi-Center, Single-Arm, Post Market Study of the MitraClip System for the Treatment of Symptomatic Mitral Regurgitation in China
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Mitral regurgitation (MR) is the most common heart valve condition in the world. MR occurs when the mitral valve does not close properly, allowing blood to leak back into the upper chamber of the heart. As a result, the heart may try to pump harder in order to compensate for the decrease in blood flow to the rest of the body. Patients with severe MR suffer from debilitating symptoms such as shortness of breath, heart palpitations, lightheadedness, and fatigue. These patients are at risk of poor quality of life, marked limitation in activity, repeated heart failure hospitalizations, and increased mortality. Chronic severe MR is often associated with heart failure and can lead to death if left untreated.
While mitral valve repair or replacement surgery is currently regarded as standard of care, many patients with clinically significant MR are at an unacceptable risk of morbidity and mortality and are therefore not appropriate surgical candidates. To optimize afterload reduction and treatment of fluid load, these patients are often treated with medical management (i.e., beta blockers, ACE inhibitors, angiotensin II receptor blockers) which may relieve MR symptoms, but does not address the underlying cause of the condition. As a result, a significant portion of patients treated medically continue to progress to heart failure and experience an increasingly debilitating quality of life. A significant unmet clinical need thus exists for the treatment of moderate-to-severe and severe MR in high surgical risk patients.
The MitraClip System has been in clinical use for treatment of significant MR since 2003. The MitraClip System received CE (Conformité Européenne) Mark for both DMR and FMR indications in March 2008 and was approved by FDA for DMR indication in October 2013 and for FMR indication in March 2019. The system is approved for use in more than 102 countries or regions worldwide. More than 100,000 patients have undergone the MitraClip procedure worldwide. On June 15, 2020, the MitraClip System has been approved for clinical use in China.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Rio Zhan
- Phone Number: +86-21-20335212
- Email: wanlei.zhan@abbott.com
Study Contact Backup
- Name: Jenny Qin
- Email: jenny.qin@abbott.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China
- Recruiting
- Fuwai Hospital Chinese Academy of Medical Sciences
-
Contact:
- Lulu Han
- Phone Number: +86-10-88398395
- Email: lchyl_fuwai@sina.com
-
Principal Investigator:
- Shengshou Hu
-
-
Fujian
-
Xiamen, Fujian, China, 361008
- Recruiting
- Xiamen Cardiovascular Hospital Xiamen University
-
Contact:
- Shaoqing Lin
- Phone Number: +86-592-2292562
- Email: xxyllwyh@163.com
-
Principal Investigator:
- Yan Wang
-
-
Guangdong
-
Shenzhen, Guangdong, China
- Recruiting
- Fuwai Hospital Chinese Academy of Medical Sciences, Shenzhen
-
Contact:
- Lixiang Liu
- Phone Number: +86-755-82180028
- Email: szfwyykjb@126.com
-
Principal Investigator:
- Xiangbin Pan
-
Zhuhai, Guangdong, China
- Withdrawn
- Zhuhai People's Hospital
-
-
Shaanxi
-
Xi'an, Shaanxi, China
- Recruiting
- The First Affiliated Hospital of Xi'an Jiaotong University
-
Contact:
- Yali Li
- Phone Number: +86-29-85323473
- Email: xjyfyllh@163.com
-
Principal Investigator:
- Zuyi Yuan
-
-
Yunnan
-
Kunming, Yunnan, China
- Withdrawn
- Fuwai Yunnan Cardiovascular Hospital
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310009
- Recruiting
- The 2nd Affiliated Hospital of Zhejiang University
-
Contact:
- Honggang Lou
- Phone Number: +86-571-87783759
- Email: HREC2013@126.com
-
Principal Investigator:
- Jian An Wang
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subjects is eligible to receive the MitraClip per the current approved MitraClip System IFU. (If any update or amendment on the IFU, the latest version of IFU shall be followed.)
- Subject is 18 years-old or above.
- Subjects who give consent for study procedure.
Exclusion Criteria:
- Subject cannot tolerate procedural anticoagulation or anti-platelet regimen.
- Subject with active endocarditis of mitral valve.
- Subject with rheumatic mitral valve disease.
- Subject with echocardiographic evidence of intracardiac, IVC or femoral venous thrombus.
- Subject is unlikely to survive the protocol follow up period of 12-months after device implant.
- Subject has insufficient or lost ability to maintain their will and rights.
- Subject is illiterate.
- Pregnant or nursing subjects and those who plan pregnancy during the study follow-up period
- Subject participates in another clinical study that may impact the follow-up or results of this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MitraClip
Subject will receive MitraClip procedure with MitraClip NTR System or MitraClip XTR System.
|
MitraClip procedure with MitraClip NTR System or MitraClip XTR System
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of Acute Procedural Success (APS)
Time Frame: Discharge/30days
|
APS is defined as successful implantation of the MitraClip device(s) with resulting MR severity of 2+ or less as determined by the ECL assessment of a discharge echocardiogram (30-day echocardiogram will be used if discharge echocardiogram is unavailable or uninterpretable).
Patients who die or who undergo mitral valve surgery before discharge are an APS failure.
|
Discharge/30days
|
Rate of freedom from Major Adverse Event (MAE)
Time Frame: 30 days
|
MAE is a composite of death, stroke, MI, renal failure, and non-elective cardiovascular surgery for device or procedure related adverse events occurring after the femoral vein puncture for transseptal access.
|
30 days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of all-cause mortality
Time Frame: 30 days, 1 year
|
Clinical Endpoints
|
30 days, 1 year
|
Rate of freedom from the components of major adverse event (MAE)
Time Frame: 30 days, 1 year
|
Clinical Endpoints
|
30 days, 1 year
|
New York Heart Association Functional Class
Time Frame: 30 days, 1 year
|
Clinical Endpoints.
New York Heart Association (NYHA) Functional Class provides a scale of extent of heart failure.
It has 4 categories of how much limitations of physical activities and heart failure symptoms and is presented as Class I, Class II, Class III and Class IV.
Higher class represent a worse outcome.
|
30 days, 1 year
|
Kansas City Cardiomyopathy Questionnaire (KCCQ) Quality of Life (QoL) scores
Time Frame: 30 days, 1 year
|
Clinical Endpoints. The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. In the KCCQ, an overall summary score can be derived from the physical function, symptom (frequency and severity), social function and quality of life domains. Scores are transformed to a range of 0-100, in which higher scores reflect better health status. |
30 days, 1 year
|
Six Minute Walk Test (6MWT) distance
Time Frame: 30 days, 1 year
|
Clinical Endpoints
|
30 days, 1 year
|
Rate of mitral valve surgery (including type of surgery), including reason for intervention
Time Frame: 30 days, 1 year
|
Clinical Endpoints
|
30 days, 1 year
|
Rate of additional MitraClip System intervention, including reason for intervention
Time Frame: 30 days, 1 year
|
Clinical Endpoints
|
30 days, 1 year
|
Number of hospitalizations and reason for hospitalization (i.e. heart failure, cardiovascular, non-cardiovascular)
Time Frame: 30 days, 1 year
|
Clinical Endpoints
|
30 days, 1 year
|
Rate of device-related complications: defined as a composite of single leaflet device attachment (SLDA), device embolization, clinically significant iatrogenic septal defect or mitral stenosis that requires intervention
Time Frame: 30 days, 1 year
|
Clinical Endpoints
|
30 days, 1 year
|
Rate of major bleeding
Time Frame: 30 days, 1 year
|
Clinical Endpoints
|
30 days, 1 year
|
Total Procedure Time: defined as the time elapsed from the first of any of the following: intravascular catheter placement, anesthesia or sedation, or transesophageal echocardiogram (TEE), to the removal of the last catheter and TEE
Time Frame: Day 0
|
Device and Procedure-Related Endpoints
|
Day 0
|
Device Procedure Time: Defined as the time elapsed from the start of the transseptal procedure to the time the Steerable Guide Catheter is removed
Time Frame: Day 0
|
Device and Procedure-Related Endpoints
|
Day 0
|
Device Time: Defined as the time the Steerable Guide Catheter is placed in the intra-atrial septum until the time the MitraClip Delivery System (CDS) is retracted into the Steerable Guide Catheter
Time Frame: Day 0
|
Device and Procedure-Related Endpoints
|
Day 0
|
Fluoroscopy Time: defined as the total minutes of exposure to fluoroscopy during the MitraClip procedure
Time Frame: Day 0
|
Device and Procedure-Related Endpoints
|
Day 0
|
Length of stay in Intensive Care Unit/Critical Care Unit/Post-Anesthesia Care Unit (ICU/CCU/PACU)
Time Frame: 30 days
|
Device and Procedure-Related Endpoints
|
30 days
|
Length of hospital stay for index MitraClip procedure
Time Frame: 30 days
|
Device and Procedure-Related Endpoints
|
30 days
|
Mitral Regurgitation Severity Grade
Time Frame: 30 days, 1 year
|
Echocardiographic Endpoints.
Mitral regurgitation (MR) severity is measured by echocardiography.
The severity is categorized in 4 grades and presented in 1+, 2+, 3+ and 4+.
Higher grade represent a worse outcome.
|
30 days, 1 year
|
Effective Regurgitant Orifice Area
Time Frame: 30 days, 1 year
|
Echocardiographic Endpoints
|
30 days, 1 year
|
Regurgitant Volume (RV)
Time Frame: 30 days, 1 year
|
Echocardiographic Endpoints
|
30 days, 1 year
|
Regurgitant Fraction (RF)
Time Frame: 30 days, 1 year
|
Echocardiographic Endpoints
|
30 days, 1 year
|
Left Ventricular End Diastolic Volume (LVEDV)
Time Frame: 30 days, 1 year
|
Echocardiographic Endpoints
|
30 days, 1 year
|
Left Ventricular End Systolic Volume (LVESV)
Time Frame: 30 days, 1 year
|
Echocardiographic Endpoints
|
30 days, 1 year
|
Left Ventricular End Diastolic Dimension (LVEDD)
Time Frame: 30 days, 1 year
|
Echocardiographic Endpoints
|
30 days, 1 year
|
Left Ventricular End Systolic Dimension (LVESD)
Time Frame: 30 days, 1 year
|
Echocardiographic Endpoints
|
30 days, 1 year
|
Left Ventricular Ejection Fraction (LVEF)
Time Frame: 30 days, 1 year
|
Echocardiographic Endpoints
|
30 days, 1 year
|
Right Ventricular Systolic Pressure (RVSP)
Time Frame: 30 days, 1 year
|
Echocardiographic Endpoints
|
30 days, 1 year
|
Mitral Valve Area (MVA)
Time Frame: 30 days, 1 year
|
Echocardiographic Endpoints
|
30 days, 1 year
|
Mean Mitral Valve Pressure Gradient (MVG)
Time Frame: 30 days, 1 year
|
Echocardiographic Endpoints
|
30 days, 1 year
|
Systolic Anterior Motion of the mitral valve (present or absent)
Time Frame: 30 days, 1 year
|
Echocardiographic Endpoints
|
30 days, 1 year
|
Forward Stroke Volume (FSV)
Time Frame: 30 days, 1 year
|
Echocardiographic Endpoints
|
30 days, 1 year
|
Cardiac Output (CO)
Time Frame: 30 days, 1 year
|
Echocardiographic Endpoints
|
30 days, 1 year
|
Cardiac Index (CI)
Time Frame: 30 days, 1 year
|
Echocardiographic Endpoints
|
30 days, 1 year
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CRD956-PMS
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mitral Regurgitation
-
Abbott Medical DevicesCompletedFunctional Mitral Regurgitation | Degenerrative Mitral RegurgitationRussian Federation
-
Ancora Heart, Inc.CompletedMitral Regurgitation | Mitral Valve Regurgitation | Functional Mitral RegurgitationAustria, Lithuania, Germany
-
Heinrich-Heine University, DuesseldorfCompletedMitral Regurgitation | Functional Mitral Regurgitation | Degenerative Mitral Valve RegurgitationGermany
-
Mitre Medical Corp.BSWRI Cardiac Imaging Core Lab (CICL)Not yet recruitingIschemic Mitral Regurgitation | Functional Mitral RegurgitationUnited States
-
Abbott Medical DevicesCompletedMitral Valve Regurgitation | Mitral Valve Incompetence | Mitral Insufficiency | Functional Mitral Regurgitation | Mitral Stenosis With InsufficiencyJapan
-
Hospital Clinic of BarcelonaAbbottUnknownMITRAL REGURGITATIONSpain
-
Edwards LifesciencesRecruitingMitral Regurgitation | Mitral Insufficiency | Functional Mitral Regurgitation | Degenerative Mitral Valve DiseaseUnited States, Canada, Switzerland, Germany
-
Boston Scientific CorporationActive, not recruitingCardiovascular Diseases | Mitral Regurgitation Functional | Mitral Valve DiseaseUnited States, Australia
-
Mardil MedicalRecruitingFunctional Mitral RegurgitationCanada, Hungary, France, Germany, Netherlands, Panama, Poland
-
Shanghai Shenqi Medical Technology Co., LtdActive, not recruitingFunctional Mitral RegurgitationChina
Clinical Trials on MitraClip procedure
-
Queen's UniversityAFP Innovation FundRecruiting
-
Abbott Medical DevicesCompletedFunctional Mitral Regurgitation | Degenerrative Mitral RegurgitationRussian Federation
-
Abbott Medical DevicesCompletedMitral Regurgitation | Mitral Valve Insufficiency | Mitral Valve Regurgitation | Mitral Valve Incompetence | Mitral InsufficiencyUnited States
-
Abbott Medical DevicesActive, not recruitingHeart Failure | Mitral Regurgitation | Mitral Valve Regurgitation | Treatment of Functional Mitral Regurgitation in Symptomatic Heart Failure SubjectsUnited States, Canada
-
Population Health Research InstituteCompletedMitral RegurgitationCanada
-
Nantes University HospitalAbbott; Ministère de la SantéRecruiting
-
Abbott Medical DevicesAbbottTerminated
-
Azienda Socio Sanitaria Territoriale degli Spedali...RecruitingHeart Failure | Mitral RegurgitationItaly
-
Fundación Investigación Sanitaria en LeónAbbott Medical DevicesCompletedMitral Regurgitation | Acute Myocardial Infarction